Is Elicio Therapeutics Stock a Good Investment?
Elicio Therapeutics Investment Advice | ELTX |
- Examine Elicio Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Elicio Therapeutics' leadership team and their track record. Good management can help Elicio Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Elicio Therapeutics' business and its evolving consumer preferences.
- Compare Elicio Therapeutics' performance and market position to its competitors. Analyze how Elicio Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Elicio Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Elicio Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Elicio Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Elicio Therapeutics is a good investment.
Sell | Buy |
Sell
Examine Elicio Therapeutics Stock
Researching Elicio Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 26.0% of the company shares are held by company insiders. The company had not issued any dividends in recent years. Elicio Therapeutics had 1:10 split on the 2nd of June 2023.
To determine if Elicio Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Elicio Therapeutics' research are outlined below:
| Elicio Therapeutics had very high historical volatility over the last 90 days | |
| Elicio Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (35.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Elicio Therapeutics generates negative cash flow from operations | |
| About 26.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Haqq Christopher of 28200 shares of Elicio Therapeutics at 5.03 subject to Rule 16b-3 |
Elicio Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Elicio Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Elicio Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Elicio Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Elicio Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-13 | 2024-06-30 | -0.96 | -0.64 | 0.32 | 33 | ||
2022-05-17 | 2022-03-31 | -4.35 | -4.8 | -0.45 | 10 | ||
2023-11-09 | 2023-09-30 | -0.8 | -1.27 | -0.47 | 58 | ||
2022-11-14 | 2022-09-30 | -3.6 | -3.0 | 0.6 | 16 | ||
2024-03-29 | 2023-12-31 | -0.78 | -1.75 | -0.97 | 124 | ||
2022-08-16 | 2022-06-30 | -4.63 | -3.0 | 1.63 | 35 |
Elicio Therapeutics Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Elicio target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Elicio Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Buy |
Most Elicio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Elicio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Elicio Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationElicio Therapeutics Target Price Projection
Elicio Therapeutics' current and average target prices are 4.60 and 12.00, respectively. The current price of Elicio Therapeutics is the price at which Elicio Therapeutics is currently trading. On the other hand, Elicio Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Elicio Therapeutics Market Quote on 5th of October 2024
Target Price
Analyst Consensus On Elicio Therapeutics Target Price
Elicio Therapeutics Analyst Ratings
Elicio Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Elicio Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Elicio Therapeutics' financials, market performance, and future outlook by experienced professionals. Elicio Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Elicio Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 52.58 M.Market Cap |
|
Elicio Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.30) | (1.36) | |
| Return On Capital Employed | (2.06) | (1.95) | |
| Return On Assets | (1.30) | (1.36) | |
| Return On Equity | (3.09) | (2.94) |
Determining Elicio Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Elicio Therapeutics is a good buy. For example, gross profit margin measures Elicio Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Elicio Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Elicio Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Elicio Therapeutics. Check Elicio Therapeutics' Beneish M Score to see the likelihood of Elicio Therapeutics' management manipulating its earnings.
Basic technical analysis of Elicio Stock
As of the 5th of October, Elicio Therapeutics shows the Downside Deviation of 4.85, coefficient of variation of 1139.91, and Mean Deviation of 3.9. Elicio Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Elicio Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Elicio Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Elicio Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Elicio Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Haqq Christopher few days ago Acquisition by Haqq Christopher of 28200 shares of Elicio Therapeutics at 5.03 subject to Rule 16b-3 | ||
Chudnovsky Yekaterina over six months ago Acquisition by Chudnovsky Yekaterina of 1032702 shares of Elicio Therapeutics at 0.01 subject to Rule 16b-3 | ||
Omenn Gilbert S over six months ago Conversion by Omenn Gilbert S of 23391 shares of Elicio Therapeutics | ||
Nissenson Allen over six months ago Acquisition by Nissenson Allen of 4100 shares of Elicio Therapeutics subject to Rule 16b-3 | ||
Nissenson Allen over six months ago Purchase by Nissenson Allen of 2037 shares of Elicio Therapeutics | ||
Neylan John F over a year ago Sale by Neylan John F of 442 shares of Elicio Therapeutics | ||
Rhodes Jennifer J over a year ago ELICIO THERAPEUTICS exotic insider transaction detected | ||
Ruffolo Robert R over a year ago ELICIO THERAPEUTICS exotic insider transaction detected | ||
Piekos Brian over a year ago Acquisition by Piekos Brian of 75484 shares of ELICIO THERAPEUTICS subject to Rule 16b-3 |
Understand Elicio Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Elicio Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0798 | |||
| Market Risk Adjusted Performance | 0.4029 | |||
| Mean Deviation | 3.9 | |||
| Semi Deviation | 4.44 | |||
| Downside Deviation | 4.85 | |||
| Coefficient Of Variation | 1139.91 | |||
| Standard Deviation | 5.52 | |||
| Variance | 30.53 | |||
| Information Ratio | 0.0667 | |||
| Jensen Alpha | 0.3462 | |||
| Total Risk Alpha | (0.25) | |||
| Sortino Ratio | 0.0759 | |||
| Treynor Ratio | 0.3929 | |||
| Maximum Drawdown | 27.87 | |||
| Value At Risk | (8.64) | |||
| Potential Upside | 8.73 | |||
| Downside Variance | 23.55 | |||
| Semi Variance | 19.7 | |||
| Expected Short fall | (4.25) | |||
| Skewness | 0.8713 | |||
| Kurtosis | 3.11 |
| Risk Adjusted Performance | 0.0798 | |||
| Market Risk Adjusted Performance | 0.4029 | |||
| Mean Deviation | 3.9 | |||
| Semi Deviation | 4.44 | |||
| Downside Deviation | 4.85 | |||
| Coefficient Of Variation | 1139.91 | |||
| Standard Deviation | 5.52 | |||
| Variance | 30.53 | |||
| Information Ratio | 0.0667 | |||
| Jensen Alpha | 0.3462 | |||
| Total Risk Alpha | (0.25) | |||
| Sortino Ratio | 0.0759 | |||
| Treynor Ratio | 0.3929 | |||
| Maximum Drawdown | 27.87 | |||
| Value At Risk | (8.64) | |||
| Potential Upside | 8.73 | |||
| Downside Variance | 23.55 | |||
| Semi Variance | 19.7 | |||
| Expected Short fall | (4.25) | |||
| Skewness | 0.8713 | |||
| Kurtosis | 3.11 |
Consider Elicio Therapeutics' intraday indicators
Elicio Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Elicio Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Elicio Therapeutics Corporate Filings
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 27th of September 2024 Other Reports | ViewVerify | |
| 17th of September 2024 Other Reports | ViewVerify | |
8K | 30th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Elicio Stock media impact
Far too much social signal, news, headlines, and media speculation about Elicio Therapeutics that are available to investors today. That information is available publicly through Elicio media outlets and privately through word of mouth or via Elicio internal channels. However, regardless of the origin, that massive amount of Elicio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Elicio Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Elicio Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Elicio Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Elicio Therapeutics alpha.
Elicio Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Elicio Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Elicio Therapeutics Corporate Management
| Joy Seymour | VP Affairs | Profile | |
| Esther Welkowsky | Senior Development | Profile | |
| Peter DeMuth | Chief Officer | Profile | |
| Michael DiVecchia | Senior Resources | Profile | |
| Megan Filoon | Secretary Counsel | Profile | |
| Brian Piekos | Chief Officer | Profile |
Additional Tools for Elicio Stock Analysis
When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.